Cargando…

Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease

The involvement of DNA damage and repair in aging processes is well established. Aging is an unequivocal risk factor for chronic neurodegenerative diseases, underscoring the relevance of investigations into the role that DNA alterations may have in the pathogenesis of these diseases. Consistently, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Milanese, Chiara, Cerri, Silvia, Ulusoy, Ayse, Gornati, Simona V., Plat, Audrey, Gabriels, Sylvia, Blandini, Fabio, Di Monte, Donato A., Hoeijmakers, Jan H., Mastroberardino, Pier G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062587/
https://www.ncbi.nlm.nih.gov/pubmed/30050065
http://dx.doi.org/10.1038/s41419-018-0848-7
_version_ 1783342401188790272
author Milanese, Chiara
Cerri, Silvia
Ulusoy, Ayse
Gornati, Simona V.
Plat, Audrey
Gabriels, Sylvia
Blandini, Fabio
Di Monte, Donato A.
Hoeijmakers, Jan H.
Mastroberardino, Pier G.
author_facet Milanese, Chiara
Cerri, Silvia
Ulusoy, Ayse
Gornati, Simona V.
Plat, Audrey
Gabriels, Sylvia
Blandini, Fabio
Di Monte, Donato A.
Hoeijmakers, Jan H.
Mastroberardino, Pier G.
author_sort Milanese, Chiara
collection PubMed
description The involvement of DNA damage and repair in aging processes is well established. Aging is an unequivocal risk factor for chronic neurodegenerative diseases, underscoring the relevance of investigations into the role that DNA alterations may have in the pathogenesis of these diseases. Consistently, even moderate impairment of DNA repair systems facilitates the onset of pathological features typical of PD that include derangement of the dopaminergic system, mitochondrial dysfunction, and alpha-synuclein stress. The latter establishes a connection between reduced DNA repair capacity and a cardinal feature of PD, alpha-synuclein pathology. It remains to be determined, however, whether alpha-synuclein stress activates in vivo the canonical signaling cascade associated with DNA damage, which is centered on the kinase ATM and substrates such as γH2Ax and 53BP1. Addressing these issues would shed light on age-related mechanisms impinging upon PD pathogenesis and neurodegeneration in particular. We analyzed two different synucleinopathy PD mouse models based either on intranigral delivery of AAV-expressing human alpha-synuclein, or intrastriatal injection of human alpha-synuclein pre-formed fibrils. In both cases, we detected a significant increase in γH2AX and 53BP1 foci, and in phospho-ATM immunoreactivity in dopaminergic neurons, which collectively indicate DNA damage and activation of the DNA damage response. Mechanistic experiments in cell cultures indicate that activation of the DNA damage response is caused, at least in part, by pro-oxidant species because it is prevented by exogenous or endogenous antioxidants, which also rescue mitochondrial anomalies caused by proteotoxic alpha-synuclein. These in vivo and in vitro findings reveal that the cellular stress mediated by alpha-synuclein—a pathological hallmark in PD—elicits DNA damage and activates the DNA damage response. The toxic cascade leading to DNA damage involves oxidant stress and mitochondrial dysfunction The data underscore the importance of DNA quality control for preservation of neuronal integrity and protection against neurodegenerative processes.
format Online
Article
Text
id pubmed-6062587
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60625872018-07-27 Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease Milanese, Chiara Cerri, Silvia Ulusoy, Ayse Gornati, Simona V. Plat, Audrey Gabriels, Sylvia Blandini, Fabio Di Monte, Donato A. Hoeijmakers, Jan H. Mastroberardino, Pier G. Cell Death Dis Article The involvement of DNA damage and repair in aging processes is well established. Aging is an unequivocal risk factor for chronic neurodegenerative diseases, underscoring the relevance of investigations into the role that DNA alterations may have in the pathogenesis of these diseases. Consistently, even moderate impairment of DNA repair systems facilitates the onset of pathological features typical of PD that include derangement of the dopaminergic system, mitochondrial dysfunction, and alpha-synuclein stress. The latter establishes a connection between reduced DNA repair capacity and a cardinal feature of PD, alpha-synuclein pathology. It remains to be determined, however, whether alpha-synuclein stress activates in vivo the canonical signaling cascade associated with DNA damage, which is centered on the kinase ATM and substrates such as γH2Ax and 53BP1. Addressing these issues would shed light on age-related mechanisms impinging upon PD pathogenesis and neurodegeneration in particular. We analyzed two different synucleinopathy PD mouse models based either on intranigral delivery of AAV-expressing human alpha-synuclein, or intrastriatal injection of human alpha-synuclein pre-formed fibrils. In both cases, we detected a significant increase in γH2AX and 53BP1 foci, and in phospho-ATM immunoreactivity in dopaminergic neurons, which collectively indicate DNA damage and activation of the DNA damage response. Mechanistic experiments in cell cultures indicate that activation of the DNA damage response is caused, at least in part, by pro-oxidant species because it is prevented by exogenous or endogenous antioxidants, which also rescue mitochondrial anomalies caused by proteotoxic alpha-synuclein. These in vivo and in vitro findings reveal that the cellular stress mediated by alpha-synuclein—a pathological hallmark in PD—elicits DNA damage and activates the DNA damage response. The toxic cascade leading to DNA damage involves oxidant stress and mitochondrial dysfunction The data underscore the importance of DNA quality control for preservation of neuronal integrity and protection against neurodegenerative processes. Nature Publishing Group UK 2018-07-26 /pmc/articles/PMC6062587/ /pubmed/30050065 http://dx.doi.org/10.1038/s41419-018-0848-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Milanese, Chiara
Cerri, Silvia
Ulusoy, Ayse
Gornati, Simona V.
Plat, Audrey
Gabriels, Sylvia
Blandini, Fabio
Di Monte, Donato A.
Hoeijmakers, Jan H.
Mastroberardino, Pier G.
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease
title Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease
title_full Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease
title_fullStr Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease
title_full_unstemmed Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease
title_short Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease
title_sort activation of the dna damage response in vivo in synucleinopathy models of parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062587/
https://www.ncbi.nlm.nih.gov/pubmed/30050065
http://dx.doi.org/10.1038/s41419-018-0848-7
work_keys_str_mv AT milanesechiara activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT cerrisilvia activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT ulusoyayse activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT gornatisimonav activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT plataudrey activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT gabrielssylvia activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT blandinifabio activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT dimontedonatoa activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT hoeijmakersjanh activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease
AT mastroberardinopierg activationofthednadamageresponseinvivoinsynucleinopathymodelsofparkinsonsdisease